Clinical review 131: Gene therapy for thyroid cancer: where do we stand?

@article{Degroot2001ClinicalR1,
  title={Clinical review 131: Gene therapy for thyroid cancer: where do we stand?},
  author={Leslie J Degroot and Rusheng Zhang},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2001},
  volume={86 7},
  pages={2923-8}
}
Although most thyroid cancers are cured by surgery and I therapy, 10–20% of patients die from advanced differentiated and anaplastic tumors. A higher proportion of medullary thyroid cancers (MTC) has an adverse prognosis. Chemotherapy has been relatively ineffective to date, although there is always hope for the future. Thus, alternative approaches, such as gene therapy, are of interest, and thyroid tumors are an especially good target, for two reasons. First, certain gene promoters expressed… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 38 references

An adenoviral vector transducing tissue specific expression of thymidine kinase under the control of thyroglobulin promoter has high specificity and low toxicity in gene therapy

  • R Zhang, FH Straus, LJ. DeGroot
  • Thyroid
  • 2001
1 Excerpt

Gene therapy for anaplastic thyroid carcinoma with replicationincompetent and -competent adenoviruses [Abstract WS-89

  • Y. Nagayama
  • Proc of the 12th Int Thyroid Congr
  • 2000
2 Excerpts

Similar Papers

Loading similar papers…